title: Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Relationships of Etravirine in HIV-1-Infected, Treatment-Experienced Children and Adolescents in PIANO.
abstract: PIANO (NCT00665847) investigated etravirine pharmacokinetics, efficacy, and safety in children and adolescents. Treatment-experienced, HIV-1-infected patients (≥6 to <18 years) received etravirine 5.2 mg/kg twice daily (maximum 200 mg twice daily) plus background antiretrovirals. A population pharmacokinetic model was developed, and etravirine C0hand AUC0-12hwere estimated. Relationships among intrinsic/extrinsic factors and etravirine pharmacokinetics and pharmacokinetics with pharmacodynamics were assessed. The best model describing etravirine pharmacokinetics consisted of a single compartment with sequential zero- and first-order absorption following a lag time. Interindividual variability terms were included on clearance (CL/F) and the first-order input rate constant (KA). The final model estimates (coefficient of variation, %) for CL/F and KA were 46.3 (11) L/h and 1.07 (34) h-1, respectively. Overall, median (range) estimated etravirine C0hand AUC0-12hwere 287 (2-2276) ng/mL and 4560 (62-28,865) ng · h/mL, respectively. Exposure was slightly lower in adolescents vs children. Sex and adherence did not affect etravirine pharmacokinetics. Factors significantly affecting etravirine exposure were body weight (higher with lower weight), race (lower in Asians than in white or black patients), and the use of certain HIV protease inhibitors. Virologic response (<50 copies/mL at week 48) was lower in the lowest etravirine AUC0-12hquartile vs the upper 3 quartiles (41% vs 67% to 76%). Rash occurred more frequently in the highest quartile than in the lower 3 quartiles (52% versus 8% to 20%). Etravirine 5.2 mg/kg twice daily in treatment-experienced, HIV-1-infected children and adolescents provides comparable exposure to that in adults receiving etravirine 200 mg twice daily and is the recommended dose for children and adolescents.
authors.affiliation: Janssen Research & Development LLC, Titusville, NJ, USA. tkakuda@its.jnj.com.
authors.forename: Thomas N
authors.initials: TN
authors.lastname: Kakuda
authors.affiliation: Janssen Research & Development, Beerse, Belgium.
authors.forename: Anne
authors.initials: A
authors.lastname: Brochot
authors.affiliation: Model Answers Pty Ltd, Brisbane, Australia.
authors.forename: Bruce
authors.initials: B
authors.lastname: Green
authors.affiliation: Janssen Infectious Diseases BVBA, Beerse, Belgium.
authors.forename: Steven
authors.initials: S
authors.lastname: Nijs
authors.affiliation: LAP&P Consultants BV, Leiden, The Netherlands.
authors.forename: Peter
authors.initials: P
authors.lastname: Vis
authors.affiliation: Janssen Infectious Diseases BVBA, Beerse, Belgium.
authors.forename: Magda
authors.initials: M
authors.lastname: Opsomer
authors.affiliation: Janssen Research & Development LLC, Titusville, NJ, USA.
authors.forename: Frank L
authors.initials: FL
authors.lastname: Tomaka
authors.affiliation: Janssen Infectious Diseases BVBA, Beerse, Belgium.
authors.forename: Richard M W
authors.initials: RM
authors.lastname: Hoetelmans
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D004334:Drug Administration Schedule; D005260:Female; D015658:HIV Infections / Q000097:blood* / Q000188:drug therapy; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D008297:Male; D009570:Nitriles; D011724:Pyridazines / Q000008:administration & dosage* / Q000097:blood* / Q000493:pharmacokinetics; D011743:Pyrimidines; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage* / Q000097:blood* / Q000493:pharmacokinetics; D016896:Treatment Outcome
chemical_list: D017320:HIV Protease Inhibitors; D009570:Nitriles; D011724:Pyridazines; D011743:Pyrimidines; D018894:Reverse Transcriptase Inhibitors; C451734:etravirine
keywords: HIV/AIDS; etravirine; pediatrics; pharmacodynamics; pharmacokinetics